{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T10:57:18Z","timestamp":1763809038830},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Neurol"],"published-print":{"date-parts":[[2011,3]]},"DOI":"10.1038\/nrneurol.2011.14","type":"journal-article","created":{"date-parts":[[2011,3,9]],"date-time":"2011-03-09T11:03:34Z","timestamp":1299668614000},"page":"132-134","source":"Crossref","is-referenced-by-count":12,"title":["Acute treatment for myasthenia gravis"],"prefix":"10.1038","volume":"7","author":[{"given":"Nils Erik","family":"Gilhus","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,3,9]]},"reference":[{"key":"BFnrneurol201114_CR1","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1111\/j.1468-1331.2010.03019.x","volume":"17","author":"GO Skeie","year":"2010","unstructured":"Skeie, G. O.  et al. Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur. J. Neurol. 17, 893\u2013902 (2010).","journal-title":"Eur. J. Neurol."},{"key":"BFnrneurol201114_CR2","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s11940-010-0070-0","volume":"12","author":"A Jani-Acsadi","year":"2010","unstructured":"Jani-Acsadi, A. & Lisak, R. P. Myasthenia gravis. Curr. Treat. Options Neurol. 12, 231\u2013243 (2010).","journal-title":"Curr. Treat. Options Neurol."},{"key":"BFnrneurol201114_CR3","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1002\/ana.22139","volume":"68","author":"A Mandawat","year":"2010","unstructured":"Mandawat, A., Kaminski, H. J., Cutter, G., Katirji, B. & Alsheklee, A. Comparative analysis of therapeutic options used for myasthenia gravis. Ann. Neurol. 68, 797\u2013805 (2010).","journal-title":"Ann. Neurol."},{"key":"BFnrneurol201114_CR4","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1136\/jnnp.2005.072355","volume":"77","author":"JF Owe","year":"2006","unstructured":"Owe, J. F., Daltveit, A. K. & Gilhus, N. E. Causes of death among patients with myasthenia gravis in Norway between 1951 and 2001. J. Neurol. Neurosurg. Psychiat. 77, 203\u2013207 (2006).","journal-title":"J. Neurol. Neurosurg. Psychiat."},{"key":"BFnrneurol201114_CR5","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1586\/14737175.9.3.351","volume":"9","author":"NE Gilhus","year":"2009","unstructured":"Gilhus, N. E. Autoimmune myasthenia gravis. Expert Rev. Neurother. 9, 351\u2013358 (2009).","journal-title":"Expert Rev. Neurother."},{"key":"BFnrneurol201114_CR6","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1001\/archneurol.2010.207","volume":"67","author":"M Cabrera Serrano","year":"2010","unstructured":"Cabrera Serrano, M. & Rabinstein, A. A. Causes and outcomes of acute neuromuscular respiratory failure. Arch. Neurol. 67, 1089\u20131094 (2010).","journal-title":"Arch. Neurol."},{"key":"BFnrneurol201114_CR7","doi-asserted-by":"crossref","unstructured":"Gajdos, P., Chevret, S. & Toyka, K. V. Intravenous immunoglobulin for myasthenia gravis. Cochrane Database of Systematic Reviews Issue 1, Art. No.: CD002277. doi: 10.1002\/14651858.CD002277.pub3 (2008).","DOI":"10.1002\/14651858.CD002277.pub3"},{"key":"BFnrneurol201114_CR8","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1159\/000320232","volume":"154","author":"S Simoens","year":"2011","unstructured":"Simoens, S. The use of intravenous immunoglobulins in Belgium. Int. Arch. Allergy Immunol. 154, 173\u2013176 (2011).","journal-title":"Int. Arch. Allergy Immunol."},{"key":"BFnrneurol201114_CR9","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1111\/j.1468-1331.2008.02246.x","volume":"15","author":"I Elovaara","year":"2008","unstructured":"Elovaara, I.  et al. EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases. Eur. J. Neurol. 15, 893\u2013908 (2008).","journal-title":"Eur. J. Neurol."},{"key":"BFnrneurol201114_CR10","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1212\/WNL.0b013e3181a41211","volume":"72","author":"A Alshekhlee","year":"2009","unstructured":"Alshekhlee, A., Miles, J. D., Katirji, B., Preston, D. C. & Kaminski, H. J. Incidence and mortality rates of myasthenia gravis and myasthenic crisis in US hospitals. Neurology 72, 1548\u20131554 (2009).","journal-title":"Neurology"}],"container-title":["Nature Reviews Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrneurol.2011.14.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrneurol.2011.14","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrneurol.2011.14.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T05:00:19Z","timestamp":1684472419000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrneurol.2011.14"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3]]},"references-count":10,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,3]]}},"alternative-id":["BFnrneurol201114"],"URL":"https:\/\/doi.org\/10.1038\/nrneurol.2011.14","relation":{},"ISSN":["1759-4758","1759-4766"],"issn-type":[{"value":"1759-4758","type":"print"},{"value":"1759-4766","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,3]]}}}